Brand Story

G&E Herbal Biotechnology Co., Ltd. was established in August 2002 and, in October of the same year, was approved by the Southern Taiwan Science Park under the Ministry of Science and Technology as a high‑tech enterprise to set up its manufacturing facility.

Drug development is inherently cross‑disciplinary. Accordingly, G&E’s R&D team integrates expertise in biochemistry, physiology, molecular biology, pharmacology, horticulture, animal testing, and quality control analysis. The team is led by Dr. Kou‑Wha Kuo, who served 23 years in the Department of Biochemistry at Kaohsiung Medical University and brings more than 40 years of drug development experience. G&E focuses on transforming natural plants into Western‑medicine‑grade botanical drugs to address clinically challenging diseases, including cancers as well as hepatic, biliary, renal, and other disorders. The company’s current paid‑in capital is NT$589,996,000.

G&E’s Plant Bioactivity and Mechanism Research Center was approved by the National Science Council. With research professionals and equipment on par with leading academic institutions, the company is recognized as one of Taiwan’s few specialized botanical new drug development centers. Over the years, G&E has successfully completed multiple government‑funded projects and academia‑industry collaborations. Notably, its new drug SR‑T100 gel has been approved by the Ministry of Health and Welfare for human clinical trials, completed Phase III clinical trials, and received FDA approval for Phase II clinical trials in the United States for the treatment of actinic keratosis and condyloma acuminatum. The company is also advancing development of an injectable formulation for treating malignant ascites in terminal cancer patients.

In addition, G&E operates government‑certified facilities, including a botanical extraction plant, food supplement production lines, skincare product manufacturing, and a PIC/S GMP pharmaceutical plant. From contracted cultivation and quality analysis to mass production, all processes are managed in‑house, enabling the company to deliver natural botanical supplements, plant‑based functional cosmetics, pharmaceuticals, and clinical trial medications with consistent quality and reliability.

G&E Herbal Biotechnology Co., Ltd. was approved for OTC listing by the Taipei Exchange on March 21, 2011 (Stock Code: 4911). For more than two decades under the leadership of Dr. Kou‑Wha Kuo, the company has operated with integrity—maintaining financial independence with no reinvestments or bank loans. All factories and land are fully owned, reflecting G&E’s strong financial foundation.

The company is deeply committed to advancing human clinical trials of its flagship new drug SR‑T100, while applying cutting‑edge pharmaceutical techniques to improve drug bioavailability and therapeutic efficacy. Its enhanced Silymarin formulation achieves the world’s highest pharmacopeia dissolution rate and has demonstrated effectiveness in treating previously intractable hepatic, biliary, and renal diseases. These achievements are propelling G&E into the international pharmaceutical arena.

Guided by a scientific R&D spirit and pragmatic approach, G&E ensures that its botanical‑based products are innovative, pioneering, and technologically advanced—earning consumer trust and professional recommendation. With leading expertise in botanical new drug development, the company is confident in building a strong brand and global reputation in the biotech industry. Supported by comprehensive data and external evaluations, G&E has become a benchmark enterprise in Taiwan’s botanical biotech sector. It is among the few companies capable of full‑spectrum botanical new drug development—from R&D through to mass production—contributing meaningfully to Taiwan’s economic growth.